CXCL1 and colorectal cancer: YTHDF1 suppresses antitumor immune responses via the m6A–p65–CXCL1/CXCR2 axis, driving colorectal cancer progression and representing a potential therapeutic target for immune checkpoint inhibitor therapy [204].